Patients also demonstrated a significantly longer median time to occurrence of the first skeletal-related event compared to placebo. Our Phase III AFFIRM trial has provided us with a very rich data set, and we look forward to presenting additional data from this trial at future medical meetings.As you know, if enzalutamide receives marketing approval, Medivation will provide 50% of the sales and medical affairs field forces supporting enzalutamide in the U.S. Since our last quarterly call, we've completed the build-out of our sales and medical affairs field forces, and we are in the final stages of preparing for launch. We continue to expect to receive FDA approval and to launch enzalutamide for our post-chemo patients in the U.S. this year. Given its potential benefits across a wide variety of prostate cancer disease states and long patent life, we and our alliance partner, Astellas, are all conducting a broad clinical development plan for enzalutamide, which we further expanded this quarter with the addition of several new trials.
Medivation Management Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts